| Literature DB >> 26446077 |
Yan Shi1, Jin-min Peng2, Xiao-yun Hu3, Yao Wang4.
Abstract
BACKGROUND: The diagnostic value of procalcitonin (PCT) for patients with autoimmune diseases (AID) remains controversial and few studies focused on ICU patients. We sought to determine its diagnostic and prognostic values in this clowd.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26446077 PMCID: PMC4596456 DOI: 10.1186/s12871-015-0122-9
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Fig. 1Study design showing patient allocation and diagnosis. SLE: systemic lupus erythematosus; DM: dermatomyositis; pSS: primary Sjogren’s syndrome; RA: rheumatoid arthritis; SSc: systemic sclerosis; MCTD: mixed connective tissue diseas; AOSD: adult-onset Still’s disease; WG: Wegener’s granulomatosis; BSI: bloodstream infection; CNS: central nervous system; CRF: chronic renal failule; ARF: acute renal failure; DAH: diffuse alveolar hemorrhage; GIB: gastrointestinal bleeding; SRC: Sclerode rmarenal crisis; ILD: interstitial lung disease
Patients’ characteristics and outcome
| Bacterial infection | Nonbacterial condition | Survivors | Non-survivors | |
|---|---|---|---|---|
| n = 39 | ||||
| Demographic characteristics | ||||
| Age, mean ± SD, yr. | 52.5 ± 13.1 | 51.8 ± 15.8 | 53.1 ± 11.7 | 52.3 ± 17.6 |
| Female, | 33 (61.1 %) | 38 (65.5 %) | 47 (64.4 %) | 24 (61.5 %) |
| Type of AID, | ||||
| SLE | 30 (55.6 %) | 29 (50 %) | 44 (60.3 %) | 15 (38.5 %)b |
| Systemic vasculitis | 5 (9.3 %) | 7 (12.1 %) | 7 (9.6 %) | 5 (12.8 %) |
| Dermatomyositis | 3 (5.6 %) | 10 (17.2 %)a | 4 (5.5 %) | 9 (23.1 %)a |
| pSS | 4 (7.4 %) | 4 (6.9 %) | 6 (8.2 %) | 2 (5.1 %) |
| RA | 3 (5.6 %) | 2 (3.4 %) | 3 (4.1 %) | 2 (5.1 %) |
| SSc | 3 (5.6 %) | 2 (3.4 %) | 3 (4.1 %) | 2 (5.1 %) |
| MCTD | 3 (5.6 %) | 2 (3.4 %) | 3 (4.1 %) | 2 (5.1 %) |
| Others | 3 (5.6 %) | 2 (3.4 %) | 3 (4.1 %) | 2 (5.1 %) |
| Comorbid conditions, | ||||
| Heart function grade > 3 (NYHA) | 4 (7,4 %) | 6 (10.3 %) | 3 (4.1 %) | 7 (17.9 %)a |
| Chronic renal insufficiency (CKD stage > 3) | 5 (9.3 %) | 6 (10.3 %) | 4 (5.5 %) | 7 (17.9 %)a |
| Prior hospitalization, days, median (range) | 3.3 (1–38) | 3.0 (1–33) | 3.2 (1–35) | 2.9 (1–38) |
| The treatment before ICU admission | ||||
| The median equivalent prednisone dose, mg/d | 43.2 ± 22.4 | 41.4 ± 25.2 | 40.2 ± 25.7 | 44.4 ± 21.5 |
| Immunosuppressants, | 11 (20.4 %) | 13 (22.4 %) | 18 (24.7 %) | 6 (15.4 %)b |
| High dose steroid, | 6 (19.4 %) | 9 (31.0 %)b | 5 (6.8 %) | 10 (25.6 %)a |
| Antibiotic therapy, | 44 (81.4 %) | 50 (86.2 %) | 61 (83.6 %) | 33 (84.6 %) |
| Reasons for ICU admission, | ||||
| Acute respiratory failure | 24 (44.4 %) | 24 (41.4 %) | 26 (35.6 %) | 22 (56.4 %)b |
| Acute kidney failure | 1 (1.9 %) | 5 (8.6 %)a | 5 (6.8 %) | 1 (2.6 %) |
| Conscious disturbance | 3 (5.6 %) | 8 (13.8 %)a | 4 (5.5 %) | 7 (17.9 %)a |
| Hypopressure of any reasons | 10 (14.8 %) | 8 (13.8 %) | 14 (19.2 %) | 4 (10.3 %)b |
| The coexistence of hypotension and respiratory failure | 16 (29.6 %) | 13 (22.4 %) | 16 (21.9 %) | 13 (33.3 %)b |
| Characteristics on admission | ||||
| Body temperature, °C | 38.2 ± 0.5 | 38.3 ± 0.7 | 38.3 ± 0.6 | 38.3 ± 0.3 |
| Leucocytes, cells/mm3 | 10,300 ± 7200 | 10,100 ± 5600 | 10,100 ± 6400 | 10,200 ± 7600 |
| Granulocyte, % | 88.5 ± 18.9 | 88.1 ± 21.5 | 88.2 ± 15.1 | 87.9 ± 13.6 |
| Neutropenia, | 4 (7.4 %) | 4 (6.9 %) | 5 (6.8 %) | 3 (7.7 %) |
| Serum creatinine, μmol/l | 106.7 ± 28.1 | 108.2 ± 35.5 | 102.5 ± 35.5 | 110.5 ± 23.7 |
| SOFA score, points | 6.8 ± 3.1 | 6.2 ± 3.5 | 5.4 ± 2.2 | 8.9 ± 2.1a |
| Organ support, | ||||
| mechanical ventilation | 48 (88.9 %) | 51 (87.9 %) | 60 (82.2 %) | 39 (100 %)b |
| renal replacement therapy | 8 (14.8 %) | 10 (17.2 %) | 7 (11.0 %) | 11 (28.2 %)a |
| vasopressor | 26 (48.1 %) | 29 (50.0 %) | 30 (41.1 %) | 25 (64.1 %)a |
| ICU new acquired severe sepsis, | 18 (33.3 %) | 23 (39.7 %) | 21 (28.8 %) | 20 (51,3 %)a |
| Duration of shock, days, median (range) | 6.5 (3–15) | 6.9 (2–14) | 3.8 (2–10) | 7.5 (7–15)a |
| ICU stay, days, median (range) | 13.1 (8–31) | 13.6 (7–33) | 12.5 (8–29) | 13.9 (7–33) |
| Appropriate treatment of the primary cause, | 28 (51.8 %) | 26 (44.8 %) | 42 (57.5 %) | 12 (30.8 %)a |
| 28-day ICU mortality, | 18 (33.3 %) | 21 (36.2 %) | - | - |
AID autoimmune diseases; SLE systemic lupus erythematosus; pSS primary Sjogren’s syndrome
RA rheumatoid arthritis; SSc systemic sclerosis; MCTD mixed connective tissue disease
aP < 0.05 versus the control group; bP < 0.20 versus the control group
Fig. 2Receiver operating curve (ROC) analysis on discrimination of bacterial infection. Peak PCT levels within 24 h (PCT) had the better performance for bacterial infection with an AUC of 0.902 and had a sensitivity of 79.6 %, specificity of 89.6 % at the threshold of 0.94 μg/L
Peak procalcitonin levels (PCTpeak) at different groups of SOFA score and septic condition
| SOFA | PCTpeak, μg/L | |
|---|---|---|
| Category of SOFA | ||
| 1–6 ( | 3.5 (2–6) | 0.68 (0.05–5.88) |
| 7–12 ( | 9.3 (7–11) | 3.85 (0.08–9.95) |
| 13–18 ( | 14.2 (13–15) | 10.58 (4.77–29.90) |
| 19–24 ( | 19 (19) | 28.74 (19.98–37.56) |
| Category according to septic condition | ||
| SIRS ( | 3.3 (2–13) | 0.67 (0.05–7.83) |
| Sepsis ( | 4.1 (3–6) | 1.73 (0.05–4.60)* |
| Severe sepsis ( | 6.1 (4–7)** | 4.81 (0.08–22.15)** |
| Septic shock ( | 9.8 (6–20)*** | 15.50 (0.08–37.56)*** |
Data presented as median values (range). SIRS, systemic inflammatory response syndrome
*P < 0.05 versus SIRS, **P < 0.05 versus sepsis, ***P < 0.05 versus severe sepsis
Procalcitonin (PCT) levels at various severities of organ dysfunction comparing patients with and without bacterial infection
| Category of SOFA score (group I/group II) | PCTpeak | ||
|---|---|---|---|
| Bacterial infection (group I) | |||
| SOFA 1–6 ( | 0.68 (0.59–5.88) | 0.14 (0.05–0.33) | 0.038 |
| 7–12 ( | 7.8 (3.52–9.95) | 0.25 (0.08–3.85) | <0.001 |
| 13–18 ( | 15.5 (13.83–29.90) | 6.30 (4.77–7.83) | 0.001 |
| 19–24 ( | 28.7 (19.98–37.56) | - | - |
Data presented as median values (range)